Literature DB >> 12091393

A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system.

Michelle E Illing1, Rahul S Rajan, Neil F Bence, Ron R Kopito.   

Abstract

The inherited retinal degenerations are typified by retinitis pigmentosa (RP), a heterogeneous group of inherited disorders that causes the destruction of photoreceptor cells, the retinal pigmented epithelium, and choroid. This group of blinding conditions affects over 1.5 million persons worldwide. Approximately 30-40% of human autosomal dominant (AD) RP is caused by dominantly inherited missense mutations in the rhodopsin gene. Here we show that P23H, the most frequent RP mutation in American patients, renders rhodopsin extremely prone to form high molecular weight oligomeric species in the cytoplasm of transfected cells. Aggregated P23H accumulates in aggresomes, which are pericentriolar inclusion bodies that require an intact microtubule cytoskeleton to form. Using fluorescence resonance energy transfer (FRET), we observe that P23H aggregates in the cytoplasm even at extremely low expression levels. Our data show that the P23H mutation destabilizes the protein and targets it for degradation by the ubiquitin proteasome system. P23H is stabilized by proteasome inhibitors and by co-expression of a dominant negative form of ubiquitin. We show that expression of P23H, but not wild-type rhodopsin, results in a generalized impairment of the ubiquitin proteasome system, suggesting a mechanism for photoreceptor degeneration that links RP to a broad class of neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12091393     DOI: 10.1074/jbc.M204955200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  130 in total

Review 1.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

2.  Molecular mechanisms of disease for mutations at Gly-90 in rhodopsin.

Authors:  Darwin Toledo; Eva Ramon; Mònica Aguilà; Arnau Cordomí; Juan J Pérez; Hugo F Mendes; Michael E Cheetham; Pere Garriga
Journal:  J Biol Chem       Date:  2011-09-22       Impact factor: 5.157

3.  Misfolded opsin mutants display elevated β-sheet structure.

Authors:  Lisa M Miller; Megan Gragg; Tae Gyun Kim; Paul S-H Park
Journal:  FEBS Lett       Date:  2015-09-07       Impact factor: 4.124

4.  Protein aggregation in retinal cells and approaches to cell protection.

Authors:  Irina Surgucheva; Natalia Ninkina; Vladimir L Buchman; Kenneth Grasing; Andrei Surguchov
Journal:  Cell Mol Neurobiol       Date:  2005-09       Impact factor: 5.046

Review 5.  Light and inherited retinal degeneration.

Authors:  D M Paskowitz; M M LaVail; J L Duncan
Journal:  Br J Ophthalmol       Date:  2006-05-17       Impact factor: 4.638

Review 6.  Regulation of G protein-coupled receptor export trafficking.

Authors:  Chunmin Dong; Catalin M Filipeanu; Matthew T Duvernay; Guangyu Wu
Journal:  Biochim Biophys Acta       Date:  2006-09-23

Review 7.  Bottlenecks in development of retinal therapeutic post-transcriptional gene silencing agents.

Authors:  Jack M Sullivan; Edwin H Yau; R Thomas Taggart; Mark C Butler; Tiffany A Kolniak
Journal:  Vision Res       Date:  2007-10-31       Impact factor: 1.886

8.  Effect of rapamycin on the fate of P23H opsin associated with retinitis pigmentosa (an American Ophthalmological Society thesis).

Authors:  Shalesh Kaushal
Journal:  Trans Am Ophthalmol Soc       Date:  2006

Review 9.  Seven-transmembrane receptors and ubiquitination.

Authors:  Sudha K Shenoy
Journal:  Circ Res       Date:  2007-04-27       Impact factor: 17.367

Review 10.  G protein-coupled receptor sorting to endosomes and lysosomes.

Authors:  Adriano Marchese; May M Paing; Brenda R S Temple; JoAnn Trejo
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.